Investor Presentaiton
Consolidated Profit & Loss Statement
Profit & Loss Statement (Rs. Crs.)
Total Revenue from Operations
Q4FY22
Q4FY21
Y-o-Y
FY22
FY21
Y-O-Y
305.9
291.7
5%
1228.3
998.0
23%
Cost of Raw Material Consumed
71.3
70.2
276.1
252.2
Laboratory Testing Charges
1.4
1.6
6.9
5.4
Employee Expenses
62.6
48.7
227.6
190.9
Other Expenses
87.9
67.6
356.2
248.2
EBIDTA (before CSR, ESOP & one time acquisition cost)
82.6
103.5
-20%
361.6
301.3
20%
EBIDTA (before CSR, ESOP & one time acquisition cost)
27.0%
35.5%
29.4%
30.2%
Margin
ESOP & CSR
3.2
6.7
11.3
13.0
One time cost of acquisition
0.0
0.0
1.4
0.0
Reported EBIDTA
79.4
96.8
-18%
348.8
288.3
21%
Reported EBIDTA Margin
26.0%
33.2%
28.4%
28.9%
Depreciation
Other Income
EBIT
18.0
14.1
63.2
45.9
1.5
2.1
13.4
12.0
62.9
84.8
-26%
299.1
254.4
18%
Finance Cost
6.5
3.1
21.6
10.1
Exceptional Item Gain / (Loss)*
0.0
0.0
15.9
0.0
Profit Before Tax
56.5
81.7
-31%
293.4
244.3
20%
Current Tax
16.3
20.3
74.7
61.0
Tax with respect to exceptional item
0.0
0.0
4.0
0.0
Profit After Tax
40.1
61.3
-35%
214.7
183.3
17%
PAT Margin
13.1%
21.0%
17.5%
18.4%
Profit After Tax (Normalised)
40.1
61.3
-35%
202.8
183.3
11%
PAT Margin (Normalised)
13.1%
21.0%
16.5%
18.4%
*Exceptional Item is on account of settlement with Global Hospital of past dues
METROPOLIS
The Pathology Specialist
✓ EBITDA was impacted by on
account of the following:-
Investments in digitalization &
marketing in a bid to improve
customer experience and faster
growth.
Increase in employee cost on
account of widening of
leadership team and front-end
staff
• Investment in lab expansion
Drop in covid margins due to
price rationalization by
Government
✓ Costs related to investments in
digitization and marketing to
partly continue in FY23
18View entire presentation